At close: December 20 at 4:00:02 PM EST
After hours: 7:56:38 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
97.0000
120.0000
--
--
--
Cost of Revenue
52.0000
77.0000
--
--
--
Gross Profit
45.0000
43.0000
--
--
--
Operating Expense
81,347.0000
50,879.0000
49,385.0000
36,928.0000
28,961.0000
Operating Income
-81,302.0000
-50,836.0000
-49,385.0000
-36,928.0000
-28,961.0000
Net Non Operating Interest Income Expense
3,883.0000
1,260.0000
797.0000
-1,442.0000
-1,503.0000
Other Income Expense
14,515.0000
-27,515.0000
2,135.0000
-365.0000
-16.0000
Pretax Income
-62,904.0000
-77,091.0000
-46,453.0000
-38,735.0000
-30,480.0000
Net Income Common Stockholders
-68,971.0000
-94,271.0000
-63,633.0000
-53,221.0000
-40,902.0000
Diluted NI Available to Com Stockholders
-68,971.0000
-94,271.0000
-63,633.0000
-53,221.0000
-40,902.0000
Basic EPS
-1.58
-1.98
-1.34
-1.12
-0.86
Diluted EPS
-1.58
-1.98
-1.34
-1.12
-0.86
Basic Average Shares
48,089.6250
47,607.2010
47,607.2010
47,607.2010
47,607.2010
Diluted Average Shares
48,089.6250
47,607.2010
82,428.3630
47,607.2010
82,428.3630
Total Operating Income as Reported
-81,302.0000
-50,836.0000
-49,385.0000
-36,928.0000
-28,961.0000
Total Expenses
81,399.0000
50,956.0000
49,385.0000
36,928.0000
28,961.0000
Net Income from Continuing & Discontinued Operation
-62,904.0000
-77,091.0000
-46,453.0000
-38,735.0000
-30,480.0000
Normalized Income
-74,713.0000
-70,297.0000
-46,277.0000
-38,379.0000
-30,465.0000
Interest Income
3,883.0000
1,260.0000
797.0000
--
--
Interest Expense
--
--
--
1,442.0000
1,503.0000
Net Interest Income
3,883.0000
1,260.0000
797.0000
-1,442.0000
-1,503.0000
EBIT
-81,302.0000
-50,836.0000
-49,385.0000
-36,928.0000
-28,977.0000
EBITDA
-80,810.0000
-50,550.0000
-48,933.0000
-36,252.0000
-28,207.0000
Reconciled Cost of Revenue
52.0000
77.0000
--
--
--
Reconciled Depreciation
492.0000
286.0000
452.0000
676.0000
770.0000
Net Income from Continuing Operation Net Minority Interest
-62,904.0000
-77,091.0000
-46,453.0000
-38,735.0000
-30,480.0000
Total Unusual Items Excluding Goodwill
11,809.0000
-6,794.0000
-176.0000
-356.0000
-15.0000
Total Unusual Items
11,809.0000
-6,794.0000
-176.0000
-356.0000
-15.0000
Normalized EBITDA
-92,619.0000
-43,756.0000
-48,757.0000
-35,896.0000
-28,192.0000
12/31/2020 - 2/2/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ANRO Alto Neuroscience, Inc.
3.8900
+4.57%
KYTX Kyverna Therapeutics, Inc.
4.0000
+3.36%
AVBP ArriVent BioPharma, Inc.
26.09
+1.72%
ALXO ALX Oncology Holdings Inc.
1.6200
+9.46%
FBLG FibroBiologics, Inc.
2.2500
+10.84%
ACRV Acrivon Therapeutics, Inc.
6.71
+0.30%
ARTV Artiva Biotherapeutics, Inc.
11.11
+11.10%
BOLD Boundless Bio, Inc.
2.5900
+2.78%
INZY Inozyme Pharma, Inc.
2.9900
+6.41%
CHRO Channel Therapeutics Corporation
0.6435
-1.45%